- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05000502
Exercise, Gut Microbiome, and Breast Cancer: Increasing Reach to Underserved Populations (EMBRACE)
March 21, 2024 updated by: Laura Q. Rogers, MD, MPH, University of Alabama at Birmingham
Understanding the impact exercise has on a cancer survivor's gut microbiome can improve the health and well-being of cancer survivors by enhancing treatments targeting the gut microbiome.
Although scientific studies support a link between exercise and the gut microbiome, rigorous randomized trials needed to confirm this causal link are limited and usually involve supervised exercise.
Hence, this proposal tests feasibility of a home-based, remote-only research protocol that is more accessible to cancer survivors unable to attend supervised exercise including but not limited to rural populations.
This study will also determine if exercise effects on the gut microbiome differ by factors such as race.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Forty physically inactive breast cancer survivors will be randomized into 10-week conditions of home-based aerobic exercise training or standard attention control.
All participants will be asked to maintain their pre-study diet and attempt to maintain their body weight while participating in the study.
Assessments will occur at baseline, week 5 (mid-intervention), and week 10 (post-intervention) by videoconference platform.
Study feasibility and changes in the gut microbiome will be assessed.
Study Type
Interventional
Enrollment (Actual)
48
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Alabama
-
Birmingham, Alabama, United States, 35294
- University of Alabama at Birmingham
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- Non-Hispanic white or black women
- Age 18-70 years
- History of breast cancer stage 0, I, II, or III
- ≥1 year post-primary cancer treatment completion
- English speaking
- Ambulates without assistance
- No antibiotics in past 90 days
- Willing to avoid taking probiotics during the study
- Has access to a safe place to perform aerobic exercise (e.g., willing to walk in neighborhood or has gym membership or owns relevant exercise equipment at home, etc.)
- Has access to good internet and WIFI and device capable of videoconferencing (the study has limited resources to loan tablets and hotspots)
Exclusion Criteria:
- Metastatic or recurrent cancer
- Another cancer diagnosis in the past 5 years (not including skin or cervical cancer in situ)
- Unstable angina
- New York Heart Association class II, III, or IV congestive heart failure
- Uncontrolled asthma
- Interstitial lung disease
- Current steroid use
- Told by a physician to only do exercise prescribed by a physician
- Dementia or organic brain syndrome
- Schizophrenia or active psychosis
- Connective tissue or rheumatologic disease
- Participating in >30 minutes of exercise on ≥3 days/week in the past six months
- Anticipate elective surgery, medication changes or antibiotics during the study
- Contraindication to ≥moderate intensity aerobic exercise
- Physical limitations that prevent engaging in ≥moderate intensity aerobic exercise
- Breastfeeding, pregnant or anticipate pregnancy during the study
- Plan to move residence during the study
- Plan to travel for more than 1 week during the study
- Anticipate trouble attending the weekly study videoconference calls
- History of bariatric surgery
- Body weight greater than 440 lbs
- Any social, psychological, or physical condition that interferes with the participant's ability to complete study activities or unduly increases study risk
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Home-based aerobic exercise training
home-based aerobic exercise condition will receive a fitness bracelet (with heart rate measurement capability) and weekly exercise counseling from an exercise trainer (i.e., exercise physiologist) by videoconference.
The weekly counseling will be guided by the fitness bracelet data (both participant and exercise trainer will share the same log in information).
The aerobic exercise progression will gradually increase duration and intensity of aerobic exercise with the goal of improving cardiorespiratory fitness.
|
A 10-week home-based exercise intervention including weekly video conferences with exercise specialists.
|
|
Active Comparator: Home-based standard attention flexibility/toning control
Home-based standard attention flexibility/toning control will receive light resistance bands, stretching/toning log book, and weekly videoconference counseling from an exercise trainer.
|
A 10-week home-based exercise intervention including weekly video conferences with exercise specialists.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility - Recruitment
Time Frame: Baseline
|
Number of participants excluded or not agreeing to participate will be measured
|
Baseline
|
|
Feasibility - Adherence to study protocol activities
Time Frame: Throughout 10 week study period
|
Feasibility measure (e.g.
percent of assessments and intervention sessions completed
|
Throughout 10 week study period
|
|
Feasibility - Attrition rates
Time Frame: Throughout 10 week study period
|
Feasibility measure of the number of participants who dropout or are withdrawn
|
Throughout 10 week study period
|
|
Feasibility - Adverse events
Time Frame: Throughout 10 week study period
|
Feasibility measure of the number of adverse events recorded by staff during the study period
|
Throughout 10 week study period
|
|
Feasibility - Participant satisfaction
Time Frame: At conclusion of 10 week study period
|
Self-Administered survey given to the participant at the conclusion of the 10 week study period
|
At conclusion of 10 week study period
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Composition of gut microbiota as measured by fecal samples
Time Frame: Baseline
|
Using standard diversity and taxa comparison metrics
|
Baseline
|
|
Composition of gut microbiota as measured by fecal samples
Time Frame: 5 weeks after baseline
|
Using standard diversity and taxa comparison metrics
|
5 weeks after baseline
|
|
Composition of gut microbiota as measured by fecal samples
Time Frame: 10 weeks after baseline
|
Using standard diversity and taxa comparison metrics
|
10 weeks after baseline
|
|
Fatigue measured through fatigue specific questionnaire
Time Frame: Baseline
|
Fatigue Symptom Inventory which contains 13 items (fatigue intensity = mean of 4 items, 1 to 10 scale; fatigue interference = mean of 7 items, 0 to 10 scale; 2 general fatigue items = 0 to 7 scale and 1 to 10 scale); higher score indicates greater fatigue
|
Baseline
|
|
Fatigue measured through fatigue specific questionnaire
Time Frame: 5 weeks after baseline
|
Fatigue Symptom Inventory which contains 13 items (fatigue intensity = mean of 4 items, 1 to 10 scale; fatigue interference = mean of 7 items, 0 to 10 scale; 2 general fatigue items = 0 to 7 scale and 1 to 10 scale); higher score indicates greater fatigue
|
5 weeks after baseline
|
|
Fatigue measured through fatigue specific questionnaire
Time Frame: 10 weeks after baseline
|
Fatigue Symptom Inventory which contains 13 items (fatigue intensity = mean of 4 items, 1 to 10 scale; fatigue interference = mean of 7 items, 0 to 10 scale; 2 general fatigue items = 0 to 7 scale and 1 to 10 scale); higher score indicates greater fatigue
|
10 weeks after baseline
|
|
Accelerometer Measured Free-living physical activity (e.g., minutes of activity)
Time Frame: Baseline
|
Motion sensor measures physical activity not observed during intervention activities
|
Baseline
|
|
Accelerometer Measured Free-living physical activity (e.g., minutes of activity)
Time Frame: 5 weeks after baseline
|
Motion sensor measures physical activity not observed during intervention activities
|
5 weeks after baseline
|
|
Accelerometer Measured Free-living physical activity (e.g., minutes of activity)
Time Frame: 10 weeks after baseline
|
Motion sensor measures physical activity not observed during intervention activities
|
10 weeks after baseline
|
|
Body fat percentage analysis using a Tanita bioelectrical impedance analysis scale
Time Frame: Baseline
|
Measurement of body fat percentage (0-100%) where a lower percentage is better.
|
Baseline
|
|
Body fat percentage analysis using a Tanita bioelectrical impedance analysis scale
Time Frame: 5 weeks after baseline
|
Measurement of body fat percentage (0-100%) where a lower percentage is better.
|
5 weeks after baseline
|
|
Body fat percentage analysis using a Tanita bioelectrical impedance analysis scale
Time Frame: 10 weeks after baseline
|
Measurement of body fat percentage (0-100%) where a lower percentage is better.
|
10 weeks after baseline
|
|
Muscle mass analysis using a Tanita bioelectrical impedance analysis scale
Time Frame: Baseline
|
Measurement of muscle mass (0 - max body weight in kilograms) where having more muscle mass can be considered positive.
|
Baseline
|
|
Muscle mass analysis using a Tanita bioelectrical impedance analysis scale
Time Frame: 5 weeks after baseline
|
Measurement of muscle mass (0 - max body weight in kilograms) where having more muscle mass can be considered positive.
|
5 weeks after baseline
|
|
Muscle mass analysis using a Tanita bioelectrical impedance analysis scale
Time Frame: 10 weeks after baseline
|
Measurement of muscle mass (0 - max body weight in kilograms) where having more muscle mass can be considered positive.
|
10 weeks after baseline
|
|
Body Mass Index analysis using a Tanita bioelectrical impedance analysis scale
Time Frame: Baseline
|
Measurement of height (m) and weight (kg) to assess body mass index, where a higher body mass index is worse.
|
Baseline
|
|
Body Mass Index analysis using a Tanita bioelectrical impedance analysis scale
Time Frame: 5 weeks after baseline
|
Measurement of height (m) and weight (kg) to assess body mass index, where a higher body mass index is worse.
|
5 weeks after baseline
|
|
Body Mass Index analysis using a Tanita bioelectrical impedance analysis scale
Time Frame: 10 weeks after baseline
|
Measurement of height (m) and weight (kg) to assess body mass index, where a higher body mass index is worse.
|
10 weeks after baseline
|
|
Change in physical performance
Time Frame: Baseline
|
Participants will complete a 2-minute step test measured by study staff through videoconference
|
Baseline
|
|
Change in physical performance
Time Frame: 5 weeks after baseline
|
Participants will complete a 2-minute step test measured by study staff through videoconference
|
5 weeks after baseline
|
|
Change in physical performance
Time Frame: 10 weeks after baseline
|
Participants will complete a 2-minute step test measured by study staff through videoconference
|
10 weeks after baseline
|
|
Depression and Anxiety measured through specific questionnaire
Time Frame: Baseline
|
Hospital Anxiety and Depression Scale [HADS] which contains 14 items (depression = total of 7 items, 0 to 3 scale; anxiety = total of 7 items, 0 to 3 scale) higher scores indicate greater depression and/or anxiety
|
Baseline
|
|
Depression and Anxiety measured through specific questionnaire
Time Frame: 5 weeks after baseline
|
Hospital Anxiety and Depression Scale [HADS] which contains 14 items (depression = total of 7 items, 0 to 3 scale; anxiety = total of 7 items, 0 to 3 scale) higher scores indicate greater depression and/or anxiety
|
5 weeks after baseline
|
|
Depression and Anxiety measured through specific questionnaire
Time Frame: 10 weeks after baseline
|
Hospital Anxiety and Depression Scale [HADS] which contains 14 items (depression = total of 7 items, 0 to 3 scale; anxiety = total of 7 items, 0 to 3 scale) higher scores indicate greater depression and/or anxiety
|
10 weeks after baseline
|
|
Sleep dysfunction measured through specific questionnaire
Time Frame: Baseline
|
Pittsburgh Sleep Quality Index which contains 7 components (sleep dysfunction = total of 7 components, 0 to 3 scale) higher score indicates worse sleep quality
|
Baseline
|
|
Sleep dysfunction measured through specific questionnaire
Time Frame: 5 weeks after baseline
|
Pittsburgh Sleep Quality Index which contains 7 components (sleep dysfunction = total of 7 components, 0 to 3 scale) higher score indicates worse sleep quality
|
5 weeks after baseline
|
|
Sleep dysfunction measured through specific questionnaire
Time Frame: 10 weeks after baseline
|
Pittsburgh Sleep Quality Index which contains 7 components (sleep dysfunction = total of 7 components, 0 to 3 scale) higher score indicates worse sleep quality
|
10 weeks after baseline
|
|
Pain measured through Patient Reported Outcomes Measurement Information System [PROMIS®]
Time Frame: Baseline
|
PROMIS® is a set of person-centered measures that evaluates and monitors physical health in adults (T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population) a higher score (higher SD) indicates greater pain
|
Baseline
|
|
Pain measured through Patient Reported Outcomes Measurement Information System [PROMIS®]
Time Frame: 5 weeks after baseline
|
PROMIS® is a set of person-centered measures that evaluates and monitors physical health in adults (T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population) a higher score (higher SD) indicates greater pain
|
5 weeks after baseline
|
|
Pain measured through Patient Reported Outcomes Measurement Information System [PROMIS®]
Time Frame: 10 weeks after baseline
|
PROMIS® is a set of person-centered measures that evaluates and monitors physical health in adults (T-score metric in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population) a higher score (higher SD) indicates greater pain
|
10 weeks after baseline
|
|
Post-traumatic stress measured through specific questionnaire
Time Frame: Baseline
|
Post-traumatic Stress Disorder Checklist (PCL) which contains 20 items (PTSD intensity = total of 20 items, 0 to 4 scale) higher score indicates greater PTSD
|
Baseline
|
|
Post-traumatic stress measured through specific questionnaire
Time Frame: 5 weeks after baseline
|
Post-traumatic Stress Disorder Checklist (PCL) which contains 20 items (PTSD intensity = total of 20 items, 0 to 4 scale) higher score indicates greater PTSD
|
5 weeks after baseline
|
|
Post-traumatic stress measured through specific questionnaire
Time Frame: 10 weeks after baseline
|
Post-traumatic Stress Disorder Checklist (PCL) which contains 20 items (PTSD intensity = total of 20 items, 0 to 4 scale) higher score indicates greater PTSD
|
10 weeks after baseline
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Laura Rogers, MD, University of Alabama at Birmingham
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 1, 2021
Primary Completion (Actual)
January 22, 2024
Study Completion (Actual)
January 31, 2024
Study Registration Dates
First Submitted
August 3, 2021
First Submitted That Met QC Criteria
August 3, 2021
First Posted (Actual)
August 11, 2021
Study Record Updates
Last Update Posted (Actual)
March 22, 2024
Last Update Submitted That Met QC Criteria
March 21, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 300007016
- BCRFA (Other Identifier: Breast Cancer Research Foundation of Alabama)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
We do not plan to share participant data.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Female Breast Cancer
-
University of Kansas Medical CenterRecruitingBreast Cancer FemaleUnited States
-
Institut fuer FrauengesundheitNovartis Pharmaceuticals; AGO Breast Study Group e.V.RecruitingBreast Cancer | Breast Neoplasms | Advanced Breast Cancer | Breast Neoplasm Female | Breast Cancer Female | HER2-negative Breast Cancer | Hormone Receptor-positive Breast CancerGermany
-
Oncoliq US IncRecruitingBreast Cancer Female | Breast Cancer Detection | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer With Low to Intermediate HER2 Expression | Breast Cancer - Female | Breast Cancer (Early Breast Cancer) | Breast Cancer - Ductal Carcinoma in Situ (DCIS) | Breast Cancer - Infiltrating...Argentina
-
Dalarna County Council, SwedenRecruitingBreast Cancer - FemaleSweden
-
Al-Quds UniversityNot yet recruitingThe Effect of Psychosocial Support on Improving Breast Cancer Patients Response to Medical TreatmentBreast Cancer - FemalePalestinian Territories
-
Izmir Biomedicine and Genome CenterDokuz Eylul University; Antalya Training and Research Hospital; Akdeniz University...Enrolling by invitationFemale Breast Cancer PatientsTurkey (Türkiye)
-
University of Central FloridaFlorida Department of HealthRecruitingBreast Cancer | Breast Cancer Female | Breast Cancer Diagnosis | Breast Cancer Survivors | Breast Cancer Detection | Breast Cancer AwarenessUnited States
-
Dana-Farber Cancer InstituteBreast Cancer Research FoundationNot yet recruitingBreast Cancer | Breast Carcinoma | ER Positive Breast Cancer | Breast Cancer - Female | PR-Positive Breast CancerUnited States
-
Carebot s.r.o.CompletedBreast Neoplasms | Breast Cancer Screening | Breast Cancer Detection | Breast Cancer - FemaleCzechia, Slovakia
-
Ahon Pharmaceutical Co., Ltd.RecruitingAdvanced Breast Cancer | Female Breast CancerChina
Clinical Trials on Home-based exercise intervention
-
Northwestern UniversityPatient-Centered Outcomes Research InstituteCompletedPeripheral Artery DiseaseUnited States
-
Goethe UniversityAgaplesion Markus Krankenhaus gGmbHCompletedAdvanced Gastrointestinal CancerGermany
-
Paul ViscuseRecruitingMetastatic Prostate Cancer | Castrate Sensitive Prostate CancerUnited States
-
Hacettepe UniversityNot yet recruitingHemophilia A Without Inhibitor
-
Jess S. GorzelitzCompletedCardiovascular Diseases | Endometrial CancerUnited States
-
Montreal Heart InstituteCompletedNeurodegenerative Diseases | Primary Progressive Aphasia | Semantic Dementia | Logopenic Progressive Aphasia | Non-fluent AphasiaCanada
-
Abant Izzet Baysal UniversityNot yet recruitingColic | Sleep Quality | PreTerm Neonate | Osteopathy | Motor Development of Premature Infants | Sensory ProfilesTurkey
-
Hadassah Medical OrganizationZinman College of Physical Education and Sports SciencesCompleted
-
Deutsches Herzzentrum MuenchenRobert-Enke-Stiftung; Institute of Preventive Pediatrics, Technical University... and other collaboratorsCompletedMotor Skills | Congenital Heart Disease | Cardiovascular Prevention | Health Related Physical FitnessGermany
-
University GhentTerminatedHypermobile Ehlers-Danlos Syndrome | Hypermobility Syndrome | Multidirectional Subluxation of ShoulderBelgium